{"id":"W2116385092","doi":"10.1200/jco.2007.13.0856","title":"Randomized Phase II Study of Gemcitabine Plus Cisplatin or Carboplatin, With or Without Cetuximab, As First-Line Therapy for Patients With Advanced or Metastatic Non–Small-Cell Lung Cancer","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":196,"is_retracted":false,"has_abstract":true,"ca_institutions":"Juravinski Hospital","funders":"Eli Lilly Canada; American Society of Clinical Oncology; Merck KGaA; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Gemcitabine; Carboplatin; Cetuximab; Lung cancer; Internal medicine; Chemotherapy; Clinical endpoint; Cisplatin; Pleural effusion; Phases of clinical research; Progression-free survival; Surgery; Gastroenterology; Oncology; Urology; Randomized controlled trial; Cancer; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002096075,0.0003393495,0.003691212,0.0001987397,0.0001313563,0.00000860997,0.0001560863,0.0001480029,0.0002760427],"category_scores_gemma":[0.001507595,0.0001414184,0.0003016736,0.0003377864,0.0001945495,0.0001410964,0.00002795939,0.0004540997,5.088787e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000307746,"about_ca_system_score_gemma":0.004353341,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001998402,"about_ca_topic_score_gemma":0.003724732,"domain_scores_codex":[0.9955436,0.0002216934,0.002972486,0.0003384809,0.0005554313,0.0003683259],"domain_scores_gemma":[0.9890295,0.005277548,0.003503183,0.0002683764,0.001530227,0.0003912075],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8915915,0.02736413,0.02337738,0.0001463087,0.004556477,0.0004285097,0.002175474,0.0004409812,0.00001454556,0.000001807692,0.0001189083,0.04978398],"study_design_scores_gemma":[0.7251917,0.2613266,0.003736509,0.0003069936,0.006316616,0.00005274522,0.0009269859,0.0008714586,0.00007250049,0.00000620202,0.001036605,0.0001550656],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9879858,0.0003715208,0.003841982,0.0005597455,0.0004367727,0.006505032,0.00003268299,0.00001171693,0.0002547173],"genre_scores_gemma":[0.9720887,0.0005449428,0.02438425,0.0007077242,0.0003078801,0.0002831998,0.00001715341,0.00006081376,0.001605337],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2339625,"threshold_uncertainty_score":0.7722641,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07258268299772243,"score_gpt":0.5066041090782099,"score_spread":0.4340214260804874,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}